A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

About the trial

Sponsor

Celgene

Tested

Revlimid (lenalidomide) (drug)

Dates

Started 2017-03-31; completion 2026-01-14

Results posted

Not yet

This post authorization safety study is designed as prospective non interventional study for patients with newly diagnosed multiple myeloma who are not eligible for transplant. The objective is to compare the incidence of cardiovascular events between patients treated with a first-line lenalidomide containing regimen and those treated with a first-line non-lenalidomide containing regimen. Treatment in both cohorts will be done according to standard care. The study will gather risk factor information at baseline and throughout follow-up. Any cardiovascular event occurring will be assessed by an independent committee. Other safety endpoints will be collected through standard procedures. Obs…

From ClinicalTrials.gov, last updated 2026-05-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Celgene Corporation reported $175 in research payments for this study in 2025 (1 payments).

Products named: Revlimid

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.